RCUS Quote, Financials, Valuation and Earnings

Gilead Sciences has a net margin of -191.67% compared to Arcus Biosciences's net margin of 16.61%. Arcus Biosciences's return on equity of -46.73% beat Gilead Sciences's return on equity of 0.64%.

Arcus Biosciences has a consensus price target of $33.20, signalling upside risk potential of 140.23%. On the other hand Gilead Sciences has an analysts' consensus of $99.96 which suggests that it could grow by 9.85%. Given that Arcus Biosciences has higher upside potential than Gilead Sciences, analysts believe Arcus Biosciences is more attractive than Gilead Sciences.

Arcus Biosciences has a beta of 0.867, which suggesting that the stock is 13.347% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.179, suggesting its less volatile than the S&P 500 by 82.12%.

Arcus Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences offers a yield of 3.39% to investors and pays a quarterly dividend of $0.77 per share. Arcus Biosciences pays -- of its earnings as a dividend. Gilead Sciences pays out 67.24% of its earnings as a dividend. Gilead Sciences's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Arcus Biosciences quarterly revenues are $48M, which are smaller than Gilead Sciences quarterly revenues of $7.5B. Arcus Biosciences's net income of -$92M is lower than Gilead Sciences's net income of $1.3B. Notably, Arcus Biosciences's price-to-earnings ratio is -- while Gilead Sciences's PE ratio is 1,011.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcus Biosciences is 4.52x versus 4.03x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of -191.67% compared to Arcus Biosciences's net margin of 8.48%. Arcus Biosciences's return on equity of -46.73% beat Eli Lilly and's return on equity of 66.4%.

Arcus Biosciences has a consensus price target of $33.20, signalling upside risk potential of 140.23%. On the other hand Eli Lilly and has an analysts' consensus of $984.05 which suggests that it could grow by 32.1%. Given that Arcus Biosciences has higher upside potential than Eli Lilly and, analysts believe Arcus Biosciences is more attractive than Eli Lilly and.

Arcus Biosciences has a beta of 0.867, which suggesting that the stock is 13.347% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.729%.

Arcus Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.7% to investors and pays a quarterly dividend of $1.30 per share. Arcus Biosciences pays -- of its earnings as a dividend. Eli Lilly and pays out 77.65% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Arcus Biosciences quarterly revenues are $48M, which are smaller than Eli Lilly and quarterly revenues of $11.4B. Arcus Biosciences's net income of -$92M is lower than Eli Lilly and's net income of $970.3M. Notably, Arcus Biosciences's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 80.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcus Biosciences is 4.52x versus 16.48x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of -191.67% compared to Arcus Biosciences's net margin of 0.7%. Arcus Biosciences's return on equity of -46.73% beat Moderna's return on equity of -17.44%.

Arcus Biosciences has a consensus price target of $33.20, signalling upside risk potential of 140.23%. On the other hand Moderna has an analysts' consensus of $69.87 which suggests that it could grow by 102.75%. Given that Arcus Biosciences has higher upside potential than Moderna, analysts believe Arcus Biosciences is more attractive than Moderna.

Arcus Biosciences has a beta of 0.867, which suggesting that the stock is 13.347% less volatile than S&P 500. In comparison Moderna has a beta of 1.597, suggesting its more volatile than the S&P 500 by 59.715%.

Arcus Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcus Biosciences pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Arcus Biosciences quarterly revenues are $48M, which are smaller than Moderna quarterly revenues of $1.9B. Arcus Biosciences's net income of -$92M is lower than Moderna's net income of $13M. Notably, Arcus Biosciences's price-to-earnings ratio is -- while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcus Biosciences is 4.52x versus 2.64x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of -191.67% compared to Arcus Biosciences's net margin of 36.03%. Arcus Biosciences's return on equity of -46.73% beat Regeneron Pharmaceuticals's return on equity of 17.19%.

Arcus Biosciences has a consensus price target of $33.20, signalling upside risk potential of 140.23%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $1,029.20 which suggests that it could grow by 48.97%. Given that Arcus Biosciences has higher upside potential than Regeneron Pharmaceuticals, analysts believe Arcus Biosciences is more attractive than Regeneron Pharmaceuticals.

Arcus Biosciences has a beta of 0.867, which suggesting that the stock is 13.347% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.098, suggesting its less volatile than the S&P 500 by 90.217%.

Arcus Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcus Biosciences pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Arcus Biosciences quarterly revenues are $48M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3.7B. Arcus Biosciences's net income of -$92M is lower than Regeneron Pharmaceuticals's net income of $1.3B. Notably, Arcus Biosciences's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 17.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcus Biosciences is 4.52x versus 5.74x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.